JPWO2018175752A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018175752A5 JPWO2018175752A5 JP2019551352A JP2019551352A JPWO2018175752A5 JP WO2018175752 A5 JPWO2018175752 A5 JP WO2018175752A5 JP 2019551352 A JP2019551352 A JP 2019551352A JP 2019551352 A JP2019551352 A JP 2019551352A JP WO2018175752 A5 JPWO2018175752 A5 JP WO2018175752A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- antibody conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940127121 immunoconjugate Drugs 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000007912 intraperitoneal administration Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000003889 eye drop Substances 0.000 claims description 4
- 229940012356 eye drops Drugs 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 4
- 238000007917 intracranial administration Methods 0.000 claims description 4
- 238000007913 intrathecal administration Methods 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 230000010412 perfusion Effects 0.000 claims description 4
- 238000001361 intraarterial administration Methods 0.000 claims description 3
- 238000000185 intracerebroventricular administration Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 230000002601 intratumoral effect Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 49
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 23
- 229920002674 hyaluronan Polymers 0.000 claims 23
- 229960003160 hyaluronic acid Drugs 0.000 claims 23
- 229920000642 polymer Polymers 0.000 claims 22
- 208000015181 infectious disease Diseases 0.000 claims 16
- 230000002458 infectious effect Effects 0.000 claims 16
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 15
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 14
- 201000011190 diabetic macular edema Diseases 0.000 claims 14
- 208000002780 macular degeneration Diseases 0.000 claims 12
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 206010010741 Conjunctivitis Diseases 0.000 claims 9
- 208000001344 Macular Edema Diseases 0.000 claims 9
- 201000002563 Histoplasmosis Diseases 0.000 claims 8
- 206010038923 Retinopathy Diseases 0.000 claims 8
- 206010046851 Uveitis Diseases 0.000 claims 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims 8
- 208000030533 eye disease Diseases 0.000 claims 8
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 7
- 108091008605 VEGF receptors Proteins 0.000 claims 7
- 210000001957 retinal vein Anatomy 0.000 claims 7
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims 6
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 5
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 5
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims 5
- 208000022873 Ocular disease Diseases 0.000 claims 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 5
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000000159 corneal neovascularization Diseases 0.000 claims 5
- 201000010206 cystoid macular edema Diseases 0.000 claims 5
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 230000002062 proliferating effect Effects 0.000 claims 5
- 230000002207 retinal effect Effects 0.000 claims 5
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 4
- 208000021089 Coats disease Diseases 0.000 claims 4
- 206010010719 Conjunctival haemorrhage Diseases 0.000 claims 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 4
- 206010013774 Dry eye Diseases 0.000 claims 4
- 208000020564 Eye injury Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 208000034508 Haemangioma of retina Diseases 0.000 claims 4
- 206010065630 Iris neovascularisation Diseases 0.000 claims 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 4
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 4
- 206010025415 Macular oedema Diseases 0.000 claims 4
- 206010029113 Neovascularisation Diseases 0.000 claims 4
- -1 PDGF Proteins 0.000 claims 4
- 201000010183 Papilledema Diseases 0.000 claims 4
- 206010033712 Papilloedema Diseases 0.000 claims 4
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 4
- 201000007737 Retinal degeneration Diseases 0.000 claims 4
- 208000017442 Retinal disease Diseases 0.000 claims 4
- 206010038910 Retinitis Diseases 0.000 claims 4
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 4
- 206010043189 Telangiectasia Diseases 0.000 claims 4
- 206010047115 Vasculitis Diseases 0.000 claims 4
- 230000000172 allergic effect Effects 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 208000010217 blepharitis Diseases 0.000 claims 4
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 4
- 208000001309 degenerative myopia Diseases 0.000 claims 4
- 230000004340 degenerative myopia Effects 0.000 claims 4
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 201000010230 macular retinal edema Diseases 0.000 claims 4
- 230000009826 neoplastic cell growth Effects 0.000 claims 4
- 201000003142 neovascular glaucoma Diseases 0.000 claims 4
- 230000035755 proliferation Effects 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 230000004258 retinal degeneration Effects 0.000 claims 4
- 208000009056 telangiectasis Diseases 0.000 claims 4
- 230000000472 traumatic effect Effects 0.000 claims 4
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical group COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 4
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 4
- 229940123429 VEGFR tyrosine kinase inhibitor Drugs 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 210000003161 choroid Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 2
- 102100038568 Age-related maculopathy susceptibility protein 2 Human genes 0.000 claims 2
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 2
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 2
- 102000009840 Angiopoietins Human genes 0.000 claims 2
- 108010009906 Angiopoietins Proteins 0.000 claims 2
- 102000018746 Apelin Human genes 0.000 claims 2
- 108010052412 Apelin Proteins 0.000 claims 2
- 102100030949 Apelin receptor Human genes 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 102000056058 Betacellulin Human genes 0.000 claims 2
- 101800001382 Betacellulin Proteins 0.000 claims 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims 2
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 2
- 102100036217 Collagen alpha-1(X) chain Human genes 0.000 claims 2
- 102000003706 Complement factor D Human genes 0.000 claims 2
- 108090000059 Complement factor D Proteins 0.000 claims 2
- 102100035321 Complement factor H-related protein 3 Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 claims 2
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 claims 2
- 101000808726 Homo sapiens Age-related maculopathy susceptibility protein 2 Proteins 0.000 claims 2
- 101000793362 Homo sapiens Apelin receptor Proteins 0.000 claims 2
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 2
- 101000875027 Homo sapiens Collagen alpha-1(X) chain Proteins 0.000 claims 2
- 101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 claims 2
- 101000941289 Homo sapiens Hepatic triacylglycerol lipase Proteins 0.000 claims 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000003816 Interleukin-13 Human genes 0.000 claims 2
- 108090000176 Interleukin-13 Proteins 0.000 claims 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 claims 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 2
- 108091007178 TNFRSF10A Proteins 0.000 claims 2
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 claims 2
- 229960002412 cediranib Drugs 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102000058223 human VEGFA Human genes 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 claims 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 108091008601 sVEGFR Proteins 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- 229940034785 sutent Drugs 0.000 claims 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010015901 Exudative retinopathy Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 230000001009 osteoporotic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 210000001210 retinal vessel Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023018086A JP2023065424A (ja) | 2017-03-22 | 2023-02-09 | 眼障害の治療のために最適化された抗体組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475163P | 2017-03-22 | 2017-03-22 | |
| US62/475,163 | 2017-03-22 | ||
| PCT/US2018/023812 WO2018175752A1 (en) | 2017-03-22 | 2018-03-22 | Optimized antibody compositions for treatment of ocular disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018086A Division JP2023065424A (ja) | 2017-03-22 | 2023-02-09 | 眼障害の治療のために最適化された抗体組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020514376A JP2020514376A (ja) | 2020-05-21 |
| JP2020514376A5 JP2020514376A5 (enExample) | 2021-05-06 |
| JPWO2018175752A5 true JPWO2018175752A5 (enExample) | 2022-09-22 |
| JP7227151B2 JP7227151B2 (ja) | 2023-02-21 |
Family
ID=61837830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551352A Active JP7227151B2 (ja) | 2017-03-22 | 2018-03-22 | 眼障害の治療のために最適化された抗体組成物 |
| JP2023018086A Withdrawn JP2023065424A (ja) | 2017-03-22 | 2023-02-09 | 眼障害の治療のために最適化された抗体組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018086A Withdrawn JP2023065424A (ja) | 2017-03-22 | 2023-02-09 | 眼障害の治療のために最適化された抗体組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11111291B2 (enExample) |
| EP (1) | EP3600442A1 (enExample) |
| JP (2) | JP7227151B2 (enExample) |
| KR (1) | KR20190138636A (enExample) |
| CN (1) | CN110612124B (enExample) |
| AR (1) | AR111249A1 (enExample) |
| AU (1) | AU2018237359B2 (enExample) |
| BR (1) | BR112019019706A2 (enExample) |
| CA (1) | CA3056248A1 (enExample) |
| CL (1) | CL2019002658A1 (enExample) |
| CO (1) | CO2019011582A2 (enExample) |
| CR (1) | CR20190481A (enExample) |
| IL (1) | IL269378A (enExample) |
| MA (1) | MA49279A (enExample) |
| MX (1) | MX2019011141A (enExample) |
| MY (1) | MY201701A (enExample) |
| PE (1) | PE20191758A1 (enExample) |
| PH (1) | PH12019502149A1 (enExample) |
| SG (1) | SG11201908650PA (enExample) |
| TW (1) | TWI839327B (enExample) |
| UA (1) | UA129242C2 (enExample) |
| WO (1) | WO2018175752A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009120893A2 (en) | 2008-03-28 | 2009-10-01 | The Regents Of The University Of California | Polypeptide-polymer conjugates and methods of use thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN113546178A (zh) | 2015-12-09 | 2021-10-26 | 加利福尼亚大学董事会 | 治疗眼部疾病或病症的方法 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| PL3448391T3 (pl) | 2016-04-27 | 2024-09-16 | AbbVie Manufacturing Management Unlimited Company | Sposoby leczenia chorób, w których jest szkodliwa aktywność il-13, przy zastosowaniu przeciwciała anty-il-13 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| JP7403553B2 (ja) * | 2019-08-06 | 2023-12-22 | エフ． ホフマン－ラ ロシュ アーゲー | 眼科の疾患の個別化された治療 |
| CA3149350A1 (en) * | 2019-08-23 | 2021-03-04 | Igm Biosciences, Inc. | Igm glycovariants |
| CN114786731A (zh) * | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| US20230201354A1 (en) * | 2020-05-15 | 2023-06-29 | The Regents Of The University Of Michigan | Carbon nanotubes and complexes thereof for treating and detecting ocular tumors |
| CN116234822A (zh) * | 2020-07-07 | 2023-06-06 | 治纳辅医药科技有限公司 | 一种包括补体途径抑制剂和血管生成抑制剂的融合蛋白及其用途 |
| CR20230009A (es) * | 2020-07-16 | 2023-01-25 | Novartis Ag | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| CN114106190B (zh) | 2020-08-31 | 2025-04-08 | 普米斯生物技术(珠海)有限公司 | 一种抗vegf/pd-l1双特异性抗体及其用途 |
| EP4232474A1 (en) | 2020-10-21 | 2023-08-30 | Boehringer Ingelheim International GmbH | Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases |
| CN117500828A (zh) * | 2021-06-04 | 2024-02-02 | 信达生物制药(苏州)有限公司 | 结合VEGF和Ang2的双特异性结合分子以及其用途 |
| CN115770477B (zh) * | 2021-09-08 | 2024-07-02 | 天津工业大学 | 一种β-环糊精修饰透明质酸钠复合纳滤膜的制备方法 |
| EP4147709A1 (en) * | 2021-09-14 | 2023-03-15 | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth | A composition comprising il-36 and/or il-18 for use in treating ocular disorders |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CR20250009A (es) | 2022-06-17 | 2025-05-07 | Apogee Biologics Inc | Anticuerpos que se unen a interleuquina 13 y métodos de uso |
| WO2024114641A1 (en) * | 2022-11-28 | 2024-06-06 | Shenzhen Oculgen Biomedical Technology Co., Ltd | C5/vegf bispecific binding molecules |
| WO2024182318A2 (en) * | 2023-02-28 | 2024-09-06 | Kodiak Sciences Inc. | Antibodies to htra1 and conjugates thereof |
| WO2024249583A2 (en) * | 2023-05-30 | 2024-12-05 | Ads Therapeutics Llc | Complement antibody-drug conjugates |
| WO2025054768A1 (en) * | 2023-09-11 | 2025-03-20 | Eluminex Biosciences (Suzhou) Limited | Multispecific fusion proteins targeting angiogenic and inflammatory factors |
| WO2025119329A1 (zh) * | 2023-12-07 | 2025-06-12 | 信达生物制药(苏州)有限公司 | 抗c5和htra1双特异性抗体及其用途 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US5144088A (en) | 1991-04-26 | 1992-09-01 | Aristech Chemical Corporation | Manufacture of neopentyl glycol (I) |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US8088604B2 (en) | 1998-04-02 | 2012-01-03 | The Board Of Regents Of The University Of Oklahoma | Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases |
| PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| AU3672800A (en) | 1999-04-09 | 2000-11-14 | Kyowa Hakko Kogyo Co. Ltd. | Method for controlling the activity of immunologically functional molecule |
| KR100850389B1 (ko) | 1999-06-25 | 2008-08-04 | 제넨테크, 인크. | 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| US20020192205A1 (en) * | 2001-05-11 | 2002-12-19 | Francis Michon | Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| GB0131112D0 (en) | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| EP1498485A4 (en) | 2002-04-09 | 2006-09-06 | Kyowa Hakko Kogyo Kk | MODIFIED GENOME CELLS |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR ENHANCING ACTIVITY OF BINDING ANTIBODY COMPOSITION WITH FC GAMMA IIIA RECEPTOR |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7608429B2 (en) | 2002-10-31 | 2009-10-27 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| AU2004205684A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005044853A2 (en) * | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| EP1654290B1 (en) * | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
| BRPI0416262B1 (pt) | 2003-11-05 | 2022-04-12 | Roche Glycart Ag | Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| ES2640767T3 (es) | 2004-08-12 | 2017-11-06 | Lipoxen Technologies Limited | Fraccionamientodepolisacáridos cargados |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| AU2010208046B2 (en) | 2009-01-29 | 2014-10-02 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| WO2010136492A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| CN102573941B (zh) * | 2009-07-30 | 2014-10-29 | 卡比兰生物外科公司 | 改性透明质酸聚合物组合物和相关的方法 |
| US20120282211A1 (en) * | 2009-11-24 | 2012-11-08 | Carnegie Mellon University | Antibodies and conjugates for modulators of angiogenesis |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| DK2600812T3 (da) | 2010-08-05 | 2021-10-18 | Forsight Vision4 Inc | Apparat til at behandle et øje |
| AU2011285637B2 (en) | 2010-08-05 | 2014-10-30 | Forsight Vision4, Inc. | Subconjunctival implant for posterior segment drug delivery |
| HUE054578T2 (hu) | 2011-09-16 | 2021-09-28 | Forsight Vision4 Inc | Fluidumcserélõ berendezés |
| AU2012322917B2 (en) | 2011-10-12 | 2016-11-03 | Ascendis Pharma Ophthalmology Division A/S | Prevention and treatment of ocular conditions |
| US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| MX361337B (es) | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| US20160302965A1 (en) | 2013-12-06 | 2016-10-20 | Forsight Vision4, Inc. | Implantable therapeutic devices |
| US10118991B2 (en) | 2014-07-18 | 2018-11-06 | Universiteit Gent | Method for the preparation of uniform, high molar mass cyclic imino ether polymers |
| MX2017003123A (es) | 2014-09-12 | 2017-05-12 | Genentech Inc | Anticuerpos y conjugados modificados geneticamente con cisteina. |
| WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
| EP4268843B1 (en) | 2014-11-07 | 2025-09-03 | F. Hoffmann-La Roche Ltd | Improved il-6 antibodies |
| WO2016073894A1 (en) * | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
| CN116987187A (zh) * | 2015-09-23 | 2023-11-03 | 豪夫迈·罗氏有限公司 | 抗-vegf抗体的优化的变体 |
-
2018
- 2018-03-22 TW TW107109759A patent/TWI839327B/zh active
- 2018-03-22 PE PE2019001916A patent/PE20191758A1/es unknown
- 2018-03-22 WO PCT/US2018/023812 patent/WO2018175752A1/en not_active Ceased
- 2018-03-22 EP EP18717180.6A patent/EP3600442A1/en active Pending
- 2018-03-22 AR ARP180100673A patent/AR111249A1/es unknown
- 2018-03-22 AU AU2018237359A patent/AU2018237359B2/en active Active
- 2018-03-22 CR CR20190481A patent/CR20190481A/es unknown
- 2018-03-22 SG SG11201908650P patent/SG11201908650PA/en unknown
- 2018-03-22 CA CA3056248A patent/CA3056248A1/en active Pending
- 2018-03-22 BR BR112019019706A patent/BR112019019706A2/pt unknown
- 2018-03-22 CN CN201880031184.4A patent/CN110612124B/zh active Active
- 2018-03-22 MX MX2019011141A patent/MX2019011141A/es unknown
- 2018-03-22 MA MA049279A patent/MA49279A/fr unknown
- 2018-03-22 MY MYPI2019005426A patent/MY201701A/en unknown
- 2018-03-22 KR KR1020197027884A patent/KR20190138636A/ko active Pending
- 2018-03-22 UA UAA201909814A patent/UA129242C2/uk unknown
- 2018-03-22 JP JP2019551352A patent/JP7227151B2/ja active Active
-
2019
- 2019-09-16 CL CL2019002658A patent/CL2019002658A1/es unknown
- 2019-09-16 IL IL26937819A patent/IL269378A/en unknown
- 2019-09-17 US US16/572,822 patent/US11111291B2/en active Active
- 2019-09-19 PH PH12019502149A patent/PH12019502149A1/en unknown
- 2019-10-18 CO CO2019011582A patent/CO2019011582A2/es unknown
-
2021
- 2021-08-03 US US17/392,943 patent/US11891437B2/en active Active
-
2023
- 2023-02-09 JP JP2023018086A patent/JP2023065424A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2018175752A5 (enExample) | ||
| JP2020514376A5 (enExample) | ||
| JP2018531005A5 (enExample) | ||
| JP7695187B2 (ja) | ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体 | |
| RU2018114723A (ru) | Оптимизированные варианты анти-vegf антител | |
| EP2021026A1 (en) | Use of il-i antibodies for treating ophthalmic disorders | |
| JP2019069973A (ja) | ｐＨ範囲で結合性が異なる薬物動態改善のための抗ＴＦＰＩ抗体変異体 | |
| TW201615216A (zh) | 抗人類ｉｌ-４受體之高親和性人類抗體 | |
| US9932397B2 (en) | VEGFA/Ang2 Compounds | |
| US20090246205A1 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
| JP2019513726A5 (enExample) | ||
| KR20210143788A (ko) | 항-il-13r 항체 또는 이의 결합 단편을 이용하는 치료 | |
| ES2966030T3 (es) | Anticuerpos anti-VEGFR-2/KDR humanos | |
| WO2017119435A1 (ja) | 高親和性抗ｖｅｇｆ抗体 | |
| JP2024528724A (ja) | 抗ｐｄ－１抗体医薬組成物及びその使用 | |
| CN114502595A (zh) | 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途 | |
| TW202421661A (zh) | Igf1r抗體 | |
| RU2019132064A (ru) | Оптимизированные композиции антител для лечения заболеваний глаз | |
| JP7691976B2 (ja) | 抗Ｎｒｐ１Ａ抗体及びその眼又は眼部疾患を治療するための使用 | |
| JPWO2021194913A5 (enExample) | ||
| TW202530256A (zh) | 多特異性抗原結合多肽之組合物及使用方法 | |
| Dugel | Reframing the retina pipeline | |
| TW202409078A (zh) | 穩定之包含抗gremlin1抗體的藥物製劑 | |
| TW202417511A (zh) | 包含抗ｖｅｇｆｒ２抗體的製劑 | |
| RU2019133326A (ru) | Пролекарственные композиции на основе гидрогеля поперечно-сшитой гиалуроновой кислоты и способы |